T1-T2N0 small cell lung cancer (SCLC) is rare but is often treated with stereotactic body radiotherapy alone, similar to the treatment of T1-T2N0 non-SCLC. This secondary analysis of a multicenter study assessed whether additional chemotherapy or prophylactic cranial irradiation improves the outcomes. Chemotherapy improved disease-free survival. The use of prophylactic cranial irradiation was not significantly associated statistically with outcomes. These results suggest that T1-T2N0 SCLC should be treated as limited-stage SCLC with no clear indication for prophylactic cranial irradiation. Background: Although T1-T2N0 nonesmall cell lung cancer can be managed with stereotactic body radiotherapy (SBRT) alone, this management has often been extrapolated to T1-T2N0 small cell lung cancer (SCLC). This secondary analysis of a multi-institutional cohort study investigated whether the addition of chemotherapy and prophylactic cranial irradiation (PCI) improved the outcomes for these patients. Materials and Methods: All cases of histologically confirmed T1-T2N0M0 SCLC were obtained from 24 institutions' prospectively collected SBRT databases. The clinical and treatment characteristics, toxicities, outcomes, and patterns of failure were assessed. We used Kaplan-Meier analysis to evaluate the survival outcomes. Univariate and multivariate analyses identified the predictors of outcomes. Results: From 24 institutions, 76 lesions were treated in 74 patients (median follow-up, 18 months). Chemotherapy and PCI were delivered in 56% and 23% of cases, respectively. The median SBRT dose per fraction was 50 Gy/5 fractions. Patients receiving chemotherapy experienced increased median disease-free survival (61.3 vs. 9.0 months; P ¼ .02) and overall survival (31.4 vs. 14.3 months; P ¼ .02). Chemotherapy independently predicted for better outcomes for disease-free survival and overall survival on multivariate analysis (P ¼ .01). Toxicities were uncommon; 5.2% experienced grade 2 pneumonitis. Post-treatment failures were most commonly distant (45.8% of recurrences), followed by nodal (25.0%), and elsewhere in the lung (20.8%). The median time to each was 5 to 7 months. Conclusion: Patients undergoing primary SBRT for T1-T2N0 SCLC should also undergo additional chemotherapy. No established role was found for PCI in this population.
Introduction
Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy, is standard for inoperable early-stage nonesmall cell lung cancer (NSCLC). [1] [2] [3] [4] [5] [6] [7] [8] However, for inoperable stage I (non-nodal) small cell lung cancer (SCLC), the National Comprehensive Cancer Network guidelines currently recommend chemotherapy with or without conventionally fractionated radiotherapy. 9 Because SBRT is associated with high local control and low toxicity, it is an attractive option for treating T1-T2N0 SCLC. 10 However, just 3 case series (totaling 22 patients) have described SBRT for this population. [11] [12] [13] Along with SBRT, the roles of chemotherapy and prophylactic cranial irradiation (PCI) in this population are uncertain. Nevertheless, the importance of this issue has been increased by the recent approval of low-dose computed tomography screening for eligible lung cancer patients. [14] [15] [16] Hence, an increase could occur in early-stage NSCLC and SCLC cases in accordance with the findings from the National Lung Screening Trial. 17 Although SBRT is an unproven treatment for these cases owing to the few data available, it is often administered with or without chemotherapy and PCI. 18 In this secondary analysis, we sought to more thoroughly address the effect of chemotherapy and PCI when added to SBRT for stage I SCLC.
Materials and Methods
The multicenter analysis examined primary stage I, biopsyproven SCLC treated with SBRT; inclusion criteria are described elsewhere. 18 The University of Nebraska Medical Center institutional review board and ethics committee approved the present study. Cases were collected by requesting academic institutions throughout the United States for all such cases in institutional SBRT databases. The exclusion criteria were a history of SCLC, except for 1 patient with a history of limited-stage SCLC without evidence of disease for 12 years before developing a solitary contralateral lung lesion that was histologically confirmed as SCLC. Two patients had presumed synchronous primary tumors (different lobes) with histologic confirmation and no nodal or distant metastasis. All patients underwent disease staging using positron emission tomography (90%) and/or pathologic nodal sampling (25%). The treatment and follow-up imaging protocols varied by institution; all centers used managed respiratory motion and imageguided radiotherapy, and the responses were evaluated using the Response Evaluation Criteria In Solid Tumors. Each clinician assigned toxicities using the Common Terminology Criteria for Adverse Events, version 4.0. In brief, the information collected included the clinical characteristics of the patients, evaluation findings, treatment, and follow-up findings. Statistical analyses were performed using Stata/MP14 software (StataCorp, College Station, TX). The tests were 2-sided, and the results were considered statistically significant at P < .05. Comparisons between groups of the proportions and mean values were performed using Fisher's exact and the Wilcoxon rank-sum test, respectively. Overall survival (OS) and disease-specific survival (DSS) refer to the interval from SBRT completion to death from any cause and death from SCLC, respectively. Disease-free survival (DFS) was measured from SBRT completion to the first recurrence of disease. Distant failure was defined as non-nodal or non-lung organs, nodal (regional) failure to lymphatic vessels in the thorax or supraclavicular area, and local failure referred to in-field failure only. In the present comorbid population, new lung lesions developing during post-SBRT follow-up often did not undergo biopsy and were considered as either second primary tumors versus recurrences (ie, following the patterns of NSCLC). These isolated or so-called oligo lung lesions are often treated definitively (in the present analysis, this decision was at the discretion of the treating physician). Therefore, the term "elsewhere lung failure" has been increasingly used, realizing that innumerable pulmonary nodules still represent distant failure. Cox proportional hazards modeling was used for multivariate analysis to evaluate the effect of several variables on the outcomes by adjusting for potential confounders (P .25, for entry). Table 1 . PCI was more commonly delivered to younger patients (P ¼ .042) and chemotherapy to those with higher performance status (P ¼ .003). Figure 1 illustrates that patients undergoing chemotherapy had increased DFS (P ¼ .01) and OS (P ¼ .01). In patients receiving chemotherapy, the median DFS and OS were 61.3 and 31.4 months versus 9.0 and 14.3 months without chemotherapy, respectively. In both groups, the median DSS was not reached. Trends toward longer OS (P ¼ .08) and DFS (P ¼ .12) were observed in the cohort receiving PCI. When adjusting for potential confounders on multivariate analysis, 18 For the cohorts receiving and not receiving chemotherapy, the complete patterns of failure are listed in Supplemental Table 1 (available in the online version). Of the 74 patients, 32 (43.2%) experienced a total of 46 recurrences. These occurred in 16 of 48 patients (33.3%) receiving chemotherapy and 16 of 26 patients (61.5%) not receiving chemotherapy (P ¼ .03). Distant recurrences were most common in both groups, followed by nodal failure. Local recurrence was uncommon in both groups. Specifically, 4 of 53 patients (7.5%; 3 of whom had received chemotherapy) who had not undergone PCI developed brain metastases; however, none of the 17 patients (0%) who had undergone PCI developed brain metastases (P ¼ .57). The interval to failure appeared numerically longer for patients receiving chemotherapy, with distant failure developing at 9.8 months with chemotherapy versus 3.6 months without (P ¼ .08), nodal failure developing at 6.3 versus 4.0 months (P ¼ .29), elsewhere lung failure developing at 16.6 versus 6.4 months (P ¼ .09), and any failure developing at 7.0 months with chemotherapy versus 3.6 months without (P ¼ .03).
Discussion
Although T1-T2N0 NSCLC can be managed with SBRT alone, this management has often been extrapolated to T1-T2N0 SCLC. Herein, we most prominently illustrate that even small, isolated SCLC lesions should be treated using the paradigm of limited-stage SCLC, for which chemotherapy is the backbone. Although the present study was designed to evaluate the feasibility of SBRT (and not to evaluate chemotherapy with or without radiotherapy) for
-Clinical Lung Cancer November 2017
Chemotherapy and SBRT in Small Cell Carcinoma nonoperative stage I SCLC, SCLC is inherently a systemic disease that requires full-course systemic therapy for all able patients. In these data, the addition of chemotherapy to SBRT was associated with more than double the OS duration (31.4 vs. 14.3 months; P ¼ .01) and a nearly sevenfold improvement in DFS (61.3 vs. 9.0 months; P ¼ .01).
The role of PCI in this population is uncertain. Although a trend was seen toward longer OS, DFS, and DSS with PCI, these differences were not statistically significant, likely because the occurrence of brain metastases was relatively low and because only 17 patients received PCI. However, a recent analysis of 954 patients with resected pT1-T2N0 SCLC from the National Cancer Data Base demonstrated that adjuvant chemotherapy, both with and without PCI, correlated positively with OS after multivariate adjustment. 19 The patients in that study represented a somewhat different population, because their disease was pathologically staged and the patients had very few comorbidities (thus decreasing risk of death from other causes). However, our data, in conjunction with that recent report (both having drawbacks of unknown baseline magnetic resonance 
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Clinical Lung Cancer November 2017 -679 imaging examination) could bring into question the value of PCI for a population with a relatively low risk of cerebral relapse. Our results are similar to those from a series of 64 patients reported in abstract form. 20 Of the 64 patients, 56% had received chemotherapy, and, similar to our results, chemotherapy appeared to be an independent factor associated with survival. The same was not true of PCI, although the report did not detail the number of brain failures. In the absence of a complete report, however, we anticipate that their results might corroborate many of our results. Both our and the aforementioned abstract conflict with results from the analogous National Cancer Data Base study, which did not find a benefit to chemotherapy. 21 However, such data are also confounded by the heterogeneity in chemotherapy delivery prior to, or after, SBRT, and whether SBRT was given as a salvage option.
The main limitation of this study was the lack of standardized evaluations, treatment, and follow-up protocols. First, it is likely that the disease for a proportion of the patients was not true T1-T2N0M0 and that occult metastases were present, because pathologic nodal staging was not performed for most patients. However, positron emission tomography staging was used for the vast majority (90%). Lung function tests also were not addressed. Additionally, specific indications for the administration of chemotherapy were unassessed. Thus, the issue of selection bias in the receipt of chemotherapy cannot be understated and is the primary drawback to conducting the largest known study of these rare cases. However, although it is possible to surmise that patients not healthy enough to receive chemotherapy died of other causes, the DFS improvement with chemotherapy also should not be ignored (in addition to the association on multivariate analysis, after adjusting for age and performance status). Furthermore, the proportion of patients with an unknown cause of death could alter the DSS data. Next, stratification by receipt of chemotherapy was performed with the omission of 4 lesions that had most likely received chemotherapy (without definitive confirmation). It is also unclear why the improvement in distant metastasis-free survival with chemotherapy was not statistically significant despite the DFS and OS improvement. However, this lack is potentially related to the relatively smaller sample size (n ¼ 21) of patients with distant metastases. Finally, the purpose of our study was not to compare the outcomes of SBRT with and without chemotherapy to the current National Comprehensive Cancer Network-recommended option of chemotherapy with and without radiotherapy, although performing local therapy in nonoperable patients might be advantageous.
Conclusion
Although T1-T2N0 NSCLC can be managed with SBRT alone, this management has often been extrapolated to T1-T2N0 SCLC. However, our experiences of SBRT for T1-T2N0 SCLC cases has shown that these cases must be treated as limited-stage SCLC; thus, chemotherapy is necessary. PCI was not shown to influence the outcomes, albeit the present study included few intracerebral events.
Clinical Practice Points
T1-T2N0 SCLC is rare but is often treated using SBRT alone, similar to T1-T2N0 NSCLC. This secondary analysis of a multicenter analysis more thoroughly assessed whether additional chemotherapy or PCI improves the outcomes. Chemotherapy improved DFS and OS in this patient population. PCI was not statistically associated with the presented outcomes. The results of the present analysis suggest that T1-T2N0 SCLC should be treated the same as limited-stage SCLC.
